Highest-materiality recent filing
Palisade Bio Q1 2026: Cash $132.6M; R&D spend up 6.4x; PALI-2108 Phase 2 UC starts Q3 2026
Cash and equivalents of $132.6M at March 31, 2026, sufficient through Phase 2 UC readout (2H 2027) and CD readout (early 2028).
Palisade Bio signs enrollment deal with Iterative Health, issues $3M stock to affiliate
Entered MSA with Iterative Health to assist with patient enrollment for Phase 2 study of PALI-2108 in ulcerative colitis.
Palisade Bio regains Nasdaq minimum bid price compliance; reports $133.3M cash
Received Nasdaq compliance letter confirming regained bid price requirement; matter closed as of Oct 15, 2025.
Palisade Bio cancels special stockholder meeting, withdraws proposals due to lack of quorum
Special meeting scheduled for Oct. 10, 2025 cancelled after failure to achieve quorum at prior adjournments.
Palisade Bio announces $3.9M warrant exercise; issues new warrants for up to 8.6M shares
Existing warrant holders exercised 4,318,905 shares at reduced price $0.9047 (from $1.40); gross proceeds ~$3.9M.
Palisade Bio Closes $5M Underwritten Public Offering of Units and Warrants
Issued 158,000 Class A Units (common + warrant) and 3,120,688 Class B Units (prefunded warrant + warrant) at $1.525/$1.5249 per unit.
Palisade Bio announces $4M private placement of common stock and pre-funded warrants
Gross proceeds of $4M from sale of 615,242 shares/pre-funded warrants at $6.5015 each.
Palisade Bio FY2023 net loss $13.1M; Nasdaq audit committee shortfall; reverse split approved
Cash and equivalents $12.5M at Dec 31, 2023; sufficient to fund operations into Q1 2025.
Palisade Bio reduces board from 8 to 4; four directors resign, Chairman changed
Directors James Neal, Stephanie Diaz, Cristina Csimma, Robert Trenschel resigned immediately; no disagreement cited.
Palisade Bio exercises warrants for $2.5M gross proceeds; exercise price reduced to $0.7313
Exercise of ~3.4M Existing Warrants at reduced price of $0.7313 per share, raising ~$2.5M gross.
Palisade Bio reports positive preclinical data for PALI-2108 UC therapy; Phase 1 planned for 2024
PALI-2108 showed colon-selective bioactivation with colon/plasma AUC ratio >200.
Palisade Bio receives Nasdaq notice for bid price below $1.00 per share
Nasdaq notified Palisade Bio on Oct 19, 2023 of non-compliance with $1.00 minimum bid price rule.
Palisade Bio appoints Mitchell Jones as CMO; grants inducement options and RSUs
Mitchell Jones, M.D., Ph.D., appointed Chief Medical Officer effective Sept 5, 2023.
Palisade Bio licenses Giiant Pharma's oral IBD drug candidates GT-2108 and GT-1908
Exclusive worldwide license for Giiant's targeted prodrug platform; lead asset GT-2108 for ulcerative colitis.
Palisade Bio CEO gets pay raise; shareholders OK equity plan amendments increasing shares
CEO J.D. Finley's base salary raised to $542,000 from $490,000; bonus target increased to 50% from 45%, effective June 1, 2023.
Palisade Bio raises $6M in registered direct offering and private placement at $2.64/share
Gross proceeds of ~$6.0M from sale of 2,272,723 shares/pre-funded warrants at $2.64 per share.
Palisade Bio closes $2.5M registered direct offering and concurrent private placement
Raised approximately $2.5M gross via 1,052,631 shares/pre-funded warrants at $2.375/share plus 1,052,631 five-year warrants at $2.375.
Palisade Bio stops Phase 2 LB1148 trial early; topline data due H1 2023
Enrolled 35 of 70 planned patients in Phase 2 PROFILE study for post-surgical adhesions; voluntarily halting further enrollment.
Palisade Bio terminates Chief Medical Officer Michael Dawson, effective Oct 11, 2022
Michael Dawson, MD, terminated as Chief Medical Officer effective October 11, 2022.
Palisade Bio CEO Thomas Hallam resigns; CFO JD Finley appointed interim CEO
CEO Thomas Hallam resigned effective Oct 11, 2022; separation agreement includes $530,000 paid over 12 months, COBRA, accelerated vesting.
Reverse split ratio range 1-for-10 to 1-for-50 approved at Oct 4 special meeting; 45.2M votes for, 2.9M against.
Reduction in force of 20% with estimated cash severance of $380,148.
Gross proceeds ~$13.8M; net proceeds ~$12.2M after underwriting discounts and estimated expenses.
Palisade Bio receives Nasdaq bid price deficiency notice; 180 days to regain compliance
Nasdaq notified on May 20, 2022 that PALI common stock closed below $1.00 minimum for 30 consecutive trading days.
Palisade Bio raises ~$2.0M in registered direct offering and warrants
Sold 3,646,690 shares at $0.55/share for gross proceeds of ~$2.0M.
On June 10, 2026 (the “Effective Date”), the Board of Directors (the “Board”) of Palisade Bio, Inc. (the “Company”) expanded the size of the Board from five to six directors and appointed Jordan Zwick to the Board.
On May 7, 2024 (the “Effective Date”), the board of directors (“Board”) of Palisade Bio, Inc. (the “Company”) appointed Margery Fischbein to the Board.
On March 4, 2024, Mary Ann Gray, Ph.D. informed the board of directors (“Board”) of Palisade Bio, Inc. (the “Company”) that she is resigning as a member of the Board effective immediately.
James Neal, Stephanie Diaz, Dr. Cristina Csimma, and Dr. Robert Trenschel (collectively, the “Resigning Directors”), informed the board of directors (“Board”) of Palisade Bio, Inc. (the “Company”) that each is resigning as a member of the Board effective immediately.
James Neal, Stephanie Diaz, Dr. Cristina Csimma, and Dr. Robert Trenschel (collectively, the “Resigning Directors”), informed the board of directors (“Board”) of Palisade Bio, Inc. (the “Company”) that each is resigning as a member of the Board effective immediately.
James Neal, Stephanie Diaz, Dr. Cristina Csimma, and Dr. Robert Trenschel (collectively, the “Resigning Directors”), informed the board of directors (“Board”) of Palisade Bio, Inc. (the “Company”) that each is resigning as a member of the Board effective immediately.
James Neal, Stephanie Diaz, Dr. Cristina Csimma, and Dr. Robert Trenschel (collectively, the “Resigning Directors”), informed the board of directors (“Board”) of Palisade Bio, Inc. (the “Company”) that each is resigning as a member of the Board effective immediately.
Mitchell Jones, M.D., Ph.D. (“Dr. Jones”) has been appointed Chief Medical Officer effective September 5, 2023
On February 2, 2023, the Company appointed Robert McRae as the Company’s Chief Operating Officer.
On February 2, 2023, the Board appointed J.D. Finley to the Board.
On November 17, 2022, the Board of Directors of Palisade Bio, Inc. (“Company”) appointed Herbert B. Slade, MD FAAAAI, to serve as the Company’s chief medical officer.
the employment of Michael Dawson, MD, was terminated by Palisade Bio, Inc.
Max materiality 0.75 · Median 0.57 · Most common event other_material